A 503A compounder is a state-licensed pharmacy or physician that makes drugs for individual patients on valid prescriptions. A 503B outsourcing facility is a compounder that has registered with FDA, follows the manufacturing quality rules that apply to drug factories, and may also supply clinics and hospitals without a patient-specific prescription. Neither kind of compounded drug is FDA-approved.1,2
Why there are two sections
FDA says compounded drugs are not reviewed for safety, effectiveness or quality before they reach patients, and that it has investigated many cases of serious injury linked to poor quality compounded drugs. In 2012, contaminated drugs from a Massachusetts compounding pharmacy caused more than 750 infections and more than 60 deaths in 20 states. Congress responded with the Drug Quality and Security Act, enacted on November 27, 2013, which confirmed section 503A and created section 503B.1
Side by side
| Question | 503A pharmacy | 503B outsourcing facility |
|---|---|---|
| Who | State-licensed pharmacist or physician | Facility registered with FDA |
| Prescription needed | Yes, for an identified patient | Not always; may fill office stock |
| Drug-factory quality rules (CGMP) | Exempt | Must comply |
| Adverse event reports to FDA | Not required | Required |
| FDA approval of the product | No | No |
FDA compounding laws and outsourcing facility pages; FDA statement on GLP-1 drugs.1,2,3
The law defines an outsourcing facility as one site that compounds sterile drugs, has chosen to register as an outsourcing facility and complies with all of section 503B. It is inspected by FDA on a risk-based schedule and must report the drugs it made over the previous six months when it registers and again every June and December; FDA keeps those reports in a searchable database.2 A 503A pharmacy, by contrast, is exempt from the drug-factory quality rules, known as current good manufacturing practice, as long as it compounds on valid prescriptions for identified patients and meets the other conditions of the section.1
What each may compound from
Compounders often start from bulk drug substances, the raw active ingredients. The rules differ.4
- 503A may use a bulk substance that meets a United States Pharmacopeia or National Formulary monograph, or is a component of an FDA-approved drug, or appears on FDA's 503A bulks list.
- 503B may use a bulk substance only to make a drug that is on FDA's drug shortage list at the time, or that appears on FDA's 503B bulks list of substances with a clinical need.
What it means for GLP-1 medicines
During the shortages, federal law let pharmacies and outsourcing facilities make what were in effect copies of Wegovy, Ozempic, Zepbound and Mounjaro. FDA declared the tirzepatide shortage over on December 19, 2024 and the semaglutide shortage over on February 21, 2025.3,5 It gave 503A pharmacies 61 and 60 days to stop, until February 18 and April 22, 2025, and outsourcing facilities 90 days in both cases, until March 19 and May 22, 2025. For 503A, the date would run longer if a court ruled later in a lawsuit brought by outsourcing facilities.5 Since then:
- a 503A pharmacy may still compound for an individual patient on a prescription, but not a product that copies an approved drug, as FDA defines a copy;
- a 503B facility may not use bulk semaglutide, because it is on neither the shortage list nor the 503B bulks list, and on April 30, 2026 FDA proposed to exclude semaglutide, tirzepatide and liraglutide from that list.
FDA statements of 2024 to 2026.5,6
By May 31, 2026 FDA had received 990 adverse event reports about compounded semaglutide and more than 730 about compounded tirzepatide.3 One more difference matters for safety tracking: FDA notes that its count of adverse events from compounded GLP-1s is probably too low, because 503A pharmacies are not required to report them.3 Our page on compounded semaglutide sets out what FDA has found and how to check a seller.
Sources
- U.S. Food and Drug Administration. Compounding laws and policies. Content current as of December 17, 2024, read November 20, 2026. fda.gov
- U.S. Food and Drug Administration. Information for outsourcing facilities. Content current as of March 29, 2022, read November 20, 2026. fda.gov
- U.S. Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss. Content current as of October 1, 2026. fda.gov
- U.S. Food and Drug Administration. Bulk drug substances used in compounding. Content current as of March 26, 2026, read November 20, 2026. fda.gov
- U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. Entries of December 19, 2024 to April 1, 2026. fda.gov
- U.S. Food and Drug Administration. FDA proposes to exclude semaglutide, tirzepatide, and liraglutide on 503B bulks list. Press announcement, April 30, 2026. fda.gov
Related analyses
Compounded semaglutide and tirzepatide in 2026: what FDA allows, what it has reported, and what to check
GLP-1 cost without insurance: every manufacturer self-pay price, dose by dose
Wegovy cost: what the pen and the pill cost with insurance, without it, and over a year
Zepbound cost: what you pay with insurance, without it, and over a year
Log which pharmacy filled each dose, so you know exactly what you took.
Open Dose Insider